Introduction: Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) is characterized by the presence of proteinase-3 (PR3) or myeloperoxidase (MPO) ANCA. In over 90% of cases, ...

Please provide your email address to receive an email when new articles are posted on . DESTIN, Fla. — Practical, individualized care for patients with antineutrophil cytoplasmic antibody-associated ...

Almost all AAV cases were diagnosed in individuals with high pretest probability, including those with renal disease, peripheral neuropathies, or pulmonary infiltrates. In clinical practice, indirect ...

Vasculitis academics have long grappled with the classification of AAV. As in the POLVAS data, GPA is a heterogenous disease and MPA is a homogenous disease. This may purely be a function of the way ...

As granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) share histopathologic and clinical features, including the presence of antineutrophil cytoplasmic autoantibodies (ANCAs), ...

Please provide your email address to receive an email when new articles are posted on . Rheumatologists should assess for PR3- and MPO-ANCA using a “high-quality antigen-specific assay” as the primary ...

For patients with GPA/MPA pathology, all scores on the Vasculitis Damage Index and ANCA Vasculitis Index of Damage increased with age. Age at diagnosis of ANCA-associated vasculitis (AAV) is ...

Granulomatosis with polyangiitis (GPA) is associated with a broad range of clinical manifestations, including renal disease. New findings by James Kelley et al. at the University of Alabama at ...

Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis is a severe condition encompassing two major syndromes: granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis) ...

ST. GALLEN, Switzerland--(BUSINESS WIRE)-- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) is pleased to announce that England’s National Institute for Health and Care Excellence (NICE) has ...

SAN CARLOS, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the outcome of the U.S. Food and Drug Administration (“FDA”) Arthritis Advisory Committee ...